Dabrafenib latest price in 2024

Dabrafenib is a drug widely used to treat certain types of cancer. It belongs to a class of drugs called BRAF (B type lymphoma kinase) inhibitors, which are used to treat two types of cancer: malignant melanoma and avesicular thyroid cancer. Both cancers are often associated with mutations in the BRAF gene, and dabrafenib works against these mutations.

Dabrafenib is now on the market in China and has been successfully included in medical insurance. Patients can purchase it domestically. However, its price is relatively high, about more than 10,000 yuan. Please consult the local hospital pharmacy for specific prices. In comparison, the price of foreign generic drugs of dabrafenib is more affordable, especially the generic drugs produced in Laos, which are only about two to three thousand yuan, which is far lower than the domestic price. It is worth mentioning that these foreign generic drugs are basically the same as the domestic original drugs in drug ingredients and therefore have similar therapeutic effects. If financial conditions are limited, patients may consider purchasing generic drugs abroad to reduce their financial burden. However, when purchasing, please make sure the source of the medicine is reliable and use it under the guidance of a doctor.

Dabrafenib is approved as part of first-line treatment for patients with BRAF V600mutated malignant melanoma, or as a second-line treatment option for advanced or metastatic melanoma. Dabrafenib is also approved for the treatment of patients with BRAF V600E mutated avesicular thyroid cancer.

The mechanism of action of dabrafenib is to inhibit the activity ofBRAFkinase, thereby preventing the growth and spread of cancer cells. BRAFkinase plays an important role in cancer cells, promoting cell proliferation and survival. Therefore, by inhibiting this kinase, dabrafenib helps slow the growth of cancer cells, extending patients' survival and improving their quality of life.

Normally, dabrafenib is used in combination with other drugs such as Trametinib (Trametinib) to achieve better therapeutic effects. Tigeol is a MEK inhibitor that can enhance its inhibitory effect on cancer cells when combined with dabrafenib.